Rex Health Ventures, established in 2012, is a North Carolina-based private equity firm that invests in and supports early-stage healthcare and related technology companies. It partners with entrepreneurs and companies to facilitate the discovery, development, and commercialization of innovative treatments, tools, and services that enhance healthcare provision. The firm leverages its resources and network, including its association with UNC REX Healthcare, to assist startups in navigating the challenges of early-stage healthcare innovation.
410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.
Arrivo BioVentures
Series B in 2023
Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in the development of biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on reformulating existing drugs and creating new chemical entities, employing its expertise to navigate regulatory strategies that streamline the approval process. By collaborating closely with regulatory bodies such as the FDA, the company aims to minimize unexpected challenges and accelerate the implementation of its clinical programs. Through its innovative approach, Arrivo BioVentures seeks to meet the demands of the biotechnology sector while prioritizing the improvement of patient outcomes.
Pryon
Funding Round in 2021
Pryon Inc. is an artificial intelligence company based in Raleigh, North Carolina, that focuses on enhancing enterprise knowledge management. Founded in 2017 by Igor Jablokov, Pryon develops an augmented intelligence platform that combines human and machine capabilities to streamline access to information across various channels and sources. The platform employs natural language processing and automated machine learning to transform unstructured data into actionable insights, thereby boosting productivity and decision-making accuracy. By utilizing a no-code approach, Pryon enables organizations to quickly harness the value of their information assets without disrupting existing operations. The company's solutions aim to simplify AI adoption, reduce complexity, and lower costs for businesses seeking to improve their workflows and knowledge utilization.
Emergo Therapeutics
Series A in 2018
Emergo Therapeutics, Inc. is a pharmaceutical company based in Durham, North Carolina, founded in 2016. The company focuses on developing therapeutic drugs aimed at modulating inflammatory cytokines and enhancing immune system function. Its primary product in development is norketotifen, which is intended for the treatment of uncomplicated influenza and flu-like illnesses. Emergo Therapeutics seeks to reduce the production of inflammatory cytokines from mast cells, with a broader goal of addressing various infectious diseases and improving health outcomes related to inflammation.
Target PharmaSolutions
Series A in 2016
TARGET PharmaSolutions, Inc. specializes in providing real-world data solutions to enhance drug development and commercialization processes. Established in 2015 in Durham, North Carolina, the company focuses on creating custom datasets and analyses to address complex healthcare evidence questions. TARGET PharmaSolutions offers comprehensive health evidence solutions that aggregate real-world data from a network of participating sites, alongside bio specimen samples and consulting services. The company emerged from the success of HCV-TARGET, a model developed for Hepatitis C that has garnered significant investment and involvement from the FDA. This background has positioned TARGET PharmaSolutions to effectively support sponsors in expanding product labels and reducing the need for costly Phase IV studies.
Arrivo BioVentures
Series A in 2016
Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in the development of biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on reformulating existing drugs and creating new chemical entities, employing its expertise to navigate regulatory strategies that streamline the approval process. By collaborating closely with regulatory bodies such as the FDA, the company aims to minimize unexpected challenges and accelerate the implementation of its clinical programs. Through its innovative approach, Arrivo BioVentures seeks to meet the demands of the biotechnology sector while prioritizing the improvement of patient outcomes.
Baebies
Series A in 2015
Baebies, Inc. is a company based in Durham, North Carolina, that specializes in manufacturing screening and pediatric testing equipment for newborns. Founded in 2014 by Richard West and Vamsee Pamula, Baebies developed its newborn screening platform, SEEKER, which is FDA authorized and CE marked. SEEKER enables the simultaneous performance of multiple assays to quantitatively measure the activity of lysosomal enzymes from a single dried blood spot specimen. Additionally, the company produces the FINDER near-patient testing equipment, which also holds CE marking, and the FINDER 1.5 platform, which includes a SARS-CoV-2 test with emergency use notification from the FDA. Baebies utilizes digital microfluidics technology, allowing for efficient diagnostics from low-volume samples, and aims to enhance early disease detection for both children and adults. The company serves hospitals and public health labs, focusing on improving newborn health outcomes and providing innovative diagnostic solutions.
Aerial BioPharma
Venture Round in 2012
Aerial BioPharma LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2011. The company specializes in drug development aimed at addressing conditions related to the central nervous system. Aerial BioPharma focuses on creating both biologics and small molecules, particularly targeting treatments for narcolepsy and other neurological disorders. By advancing innovative therapies, the company aims to enhance treatment options available to healthcare institutions and improve patient outcomes in the realm of central nervous system disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.